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Abstract Niemann-Pick type C1 (NPC1) disease is a
lysosomal lipid storage disorder caused by mutations
of the NPC1 gene. More than 300 disease-associated
mutations are reported in patients, resulting in
abnormal accumulation of unesterified cholesterol,
glycosphingolipids, and other lipids in late endo-
somes and lysosomes (LE/Ly) of many cell types.
Previously, we showed that treatment of many
different NPC1 mutant fibroblasts with histone
deacetylase inhibitors resulted in reduction of
cholesterol storage, and we found that this was asso-
ciated with enhanced exit of the NPC1 protein from
the endoplasmic reticulum and delivery to LE/Ly.
This suggested that histone deacetylase inhibitors
may work through changes in protein chaperones to
enhance the folding of NPC1 mutants, allowing them
to be delivered to LE/Ly. In this study, we evaluated
the effect of several HSP90 inhibitors on NPC1I1061T
skin fibroblasts. We found that HSP90 inhibition
resulted in clearance of cholesterol from LE/Ly, and
this was associated with enhanced delivery of the
mutant NPC1I1061T protein to LE/Ly. We also
observed that inhibition of HSP90 increased the
expression of HSP70, and overexpression of HSP70
also reduced cholesterol storage in NPC1I1061T fibro-
blasts. However, we did not see correction of choles-
terol storage by arimoclomol, a drug that is reported
to increase HSP70 expression, at doses up to
0.5 mM. The increase in other chaperones as a
consequence of HSP90 improves folding of NPC1
protein and relieves cholesterol accumulation in
NPC1 mutant fibroblasts.
Supplementary key words cholesterol • drug therapy •
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Niemann-Pick type C1 (NPC1) disease is a neuro-
visceral lysosomal storage disease caused by mutations
in both alleles of the NPC1 gene. The incidence of
occurrence in juveniles is estimated to be about one in
92,000, but with the inclusion of mutations associated
with late-onset disease, the frequency increases to one
in 20,000–36,000 (1). Over 300 disease-associated muta-
tions are reported (1–6), and biallelic mutations lead to
abnormal accumulation of unesterified cholesterol,
glycosphingolipids, and other lipids in late endosomes
and lysosomes (LE/Ly) of many cell types. The most
common mutation, I1061T, is present in at least one
allele of about 20% of patients (7). The clinical spectrum
of NPC1 disease is very broad, ranging from a rapidly
progressing fatal neonatal disorder to adult-onset neu-
rodegeneration (8–10). NPC1 is a lysosomal glycoprotein
with 13-transmembrane domains that is synthesized and
folded with the aid of chaperones in the endoplasmic
reticulum (ER) (11–14), where it acquires 14 N-linked
glycans (15, 16). After exit from the ER, the NPC1 pro-
tein is exported to the Golgi and subsequently targeted
to LE/Ly compartments (17). Many mutations in NPC1
result in protein misfolding and impaired trafficking
of the protein out of ER, followed by protein degra-
dation (ER-associated protein degradation) (11, 18). This
results in significant reduction of NPC1 protein levels
compared withWT cells (11, 18). Lack of sufficient NPC1
protein in the LE/Ly leads to impaired cholesterol exit
from these organelles.
There is no Food and Drug Administration-approved
therapy to treat NPC1 disease. Intrathecal delivery of
2-hydroxypropyl beta-cyclodextrin (HPCD) was shown
to slow disease progression in a phase 1/2a trial (19, 20),
prompting a phase 2b/3 trial. A limitation of HPCD is
that it does not cross the blood-brain barrier, requiring
direct injection into the CNS. In a search for an orally
available treatment, we showed that histone deacetylase
inhibitor (HDACi) treatment of skin fibroblasts results
in increased expression of NPC1 protein in mutant cells
because of enhanced folding and exit from the ER (21).
Using an engineered human cell line, we also observed
that broad-spectrum HDACis can correct the NPC1
*For correspondence: Frederick R. Maxfield, frmaxfie@med.
cornell.edu.
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cholesterol storage defect in 60 of the 81 NPC1 mutants
tested (18). These studies indicated that many of the
mutant proteins could function adequately if they were
delivered to LE/Ly. However, a study in a mouse model
of NPC1I1061T (22) indicated that an HDACi (Vorinostat)
provided no benefit in a whole animal model (23).
Nevertheless, the correction in cell culture indicated
that the HDACis were assisting in correction of the
disease phenotype for many NPC1 mutations. In order
to understand the molecular mechanism of HDACi on
NPC1, we considered potential cellular effects of
HDACi treatment. It has been shown that the
NPC1I1061T mutant protein undergoes ER-associated
protein degradation, presumably associated with the
inability to fold efficiently in the ER (11). Boosting
chaperone activity has been proposed as a method to
correct the defect in NPC1 mutant cells (12, 24–26).
Changes in molecular chaperone activity are one of the
many consequences of HDACi treatment (14, 27, 28). A
quantitative proteomic analysis of the response to
HDACi in NPC1 human fibroblasts revealed that the
expression of proteins associated with protein folding
was modulated (29). A detailed study of the response of
many NPC1 mutations to allosteric modulators showed
that many of the mutations were rescued to some de-
gree by these modulators, which alter the interactions
of HSP70 with cochaperones (14). It has been shown
that HSP90 as well as HSP70 can play a role in stabili-
zation and correct folding of NPC1 (12).
Several HSP90 inhibitors have gone through exten-
sive clinical testing as potential cancer therapeutics (30).
We tested the effect of HSP90 inhibitors on the
expression, folding, and activity of NPC1 in human
fibroblasts that were homozygous for the NPC1I1061T
allele, expecting that this would exacerbate the
phenotype. Surprisingly, we found that HSP90 inhibi-
tion aided in transporting mutant NPC1 protein from
the ER to LE/Ly, which led to increased clearance of
cholesterol from LE/Ly. Molecular chaperones form a
complex network to assist in protein folding in cells (31).
HSP70 family members are key members of the chap-
erone family, and we confirmed that HSP90 inhibition
led to an increase in HSP70 expression as reported
previously (32, 33). In addition, transfection of cells with
HSP701A (HSPA1A) led to a reduction in cholesterol
storage in NPC1I1061T cells. We tested arimoclomol,
which is reported to increase expression of HSP70 and
other chaperones (34), but we did not see an increase in




Gibco® McCoy's 5A medium, MEM, FBS, HBSS, penicillin/
streptomycin, Geneticin (G418), AlexaFluor-546 N-hydroxy
succinimidyl ester, and AlexaFluor 546 goat anti-rabbit and
AlexaFluor 488 goat anti-rat antibody were purchased from
Invitrogen Life Technologies Corporation (Carlsbad, CA).
HSP90 inhibitors were from various suppliers: 17-AAG (Gel-
danamycin) from Reagent Direct (Encinitas, CA), AUY922
(luminespib), ganetespib, and AT13387 (onalespib) from Sell-
eckchem (Houston, TX) or from the Blagg laboratory at Notre
Dame (35), SNX2112 from Esanex (Indianapolis, IN), TAS-116
from Taiho Pharmaceuticals (Tokyo, Japan), and arimoclo-
mol maleate (arimoclomol) from MedKoo Biosciences.
Glucose-regulated protein 94 (GRP94) inhibitors were ob-
tained from the Blagg laboratory and prepared as described
in references in Table 1. All compounds were dissolved at 10
or 1 mM in dimethyl sulfoxide (DMSO) and stored at −20◦C.
AcetylatedLDLwas prepared by acetylation ofLDLwith acetic
anhydride (40). AlexaFluor-546 labeled human LDL (LDL-
A546) was prepared as described (41, 42). Rabbit polyclonal
antihuman NPC1 (p-Rab anti-hNPC1) antibody was purchased
from Abcam (Cambridge, MA), rabbit polyclonal anti-HSP40
(p-Rab anti-HSP40), anti-HSP70 (p-Rab anti-HSP70), and anti-
HSP90 (p-Rab anti-HSP90) were purchased from Cell
Signaling (Danvers, MA). A p-Rab anti-hNPC1 antibody was
used for EndoH Western blotting assay. All other chemicals,
including (DMSO, 99% fatty-acid free bovine serum albumin,
filipin, paraformaldehyde (PFA), and Hepes were purchased
fromSigmaChemical (St. Louis,MO). Draq5was fromBiostatus
(Leicestershire, UK), and Metamorph image-analysis software
was from Molecular Devices (Downington, PA).
Cell culture
Human fibroblast cells. Human NPC1 fibroblasts GM18453
(homozygous NPC1 mutant I1061T) were from Coriell Insti-
tute (Camden, NJ). All human skin fibroblasts were main-
tained in MEM supplemented with 10% FBS. For the inhibitor
treatments, cells were maintained in MEM supplemented with
5.5% FBS and 20 mM Hepes.
NPC1 null cells (U2OS-SRAshNPC1). Stable U2OS-SRA-shNPC1
cells (18) were cultured in McCoy's 5A medium supplemented
with 10% FBS, 50-units/ml penicillin, 50 μg/ml streptomycin,
5 μg/ml puromycin, and 1 mg/ml G418.
Effect of HSP90 and GRP94 inhibitor treatment on
human fibroblasts
The dose dependence of six HSP90 inhibitors (17-AAG,
AUY922, ganetespib, AT13387, SNX2112, and TAS-116) and
Grp94 inhibitors (BB1-5) was determined after 72-h treatment
of NPC1 fibroblasts. Human NPC1I1061T fibroblasts were
seeded in 384-well plates at 450 cells/well in growth medium
on day 1. After overnight incubation, compounds were added
at six different doses diluted in growthmedium supplemented
with 20 mM Hepes buffer and 5.5% FBS. DMSO was used as a




for GRP94GRP94 HSP90α HSP90β
BB-1 0.44 8.3 ND 19 (36)
BB-2 0.2 8.1 ND 41 (36)
BB-3 0.54 39.2 ND 73 (37)
BB-4 8.5 18.2 0.44 42 (38)
BB-5 0.44 >100 ND >200 (39)
ND, not determined.
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control in each plate for each concentration. After 72 h, the
plate was washed with PBS three times, fixed with 1.5% PFA,
and stained with 50 μg/ml filipin and nuclear stain Draq5.
Measurements were made from four wells for each condition
in each experiment, and the experiment was repeated three
times. Images were acquired on an ImageXpressMicro auto-
matic fluorescence microscope, at four sites per well and
analyzed to obtain the lysosome-like storage organelles (LSOs)
compartment ratio, which is a measure of filipin labeling of
stored cholesterol per cell (43). In other words, the LSO ratio is
the perinuclear filipin intensity (PFI) per cell. A high PFI per
cell is associated with high levels of cholesterol in LE/Ly.
Removal of this cholesterol leads to reduction in the PFI per
cell. The PFI per cell for each concentration was normalized to
the corresponding DMSO-treated control.
Time and dose-dependence assay. The dose dependence of two
HSP90 inhibitors, 17-AAG and AUY922, was determined as a
function of time after 24, 48, and 72 h treatment of NPC1I1061T
fibroblasts (GM18453). To maintain the same density of cells
at the final time point, compounds were added chronologi-
cally. After overnight incubation, compounds were diluted in
growth medium supplemented with 20 mM Hepes buffer and
1% FBS and added in the first plate (for 72-h time point). In
the second plate, compounds were added 48 h after seeding
the cells and allowed to incubate for 48 h. In the third plate,
compounds were added 72 h after seeding the cells and
allowed to incubate for 24 h. DMSO was used as a control in
each plate for each concentration. All three plates were
rinsed, fixed, stained, and analyzed as described previously.
Fluorescence microscopy
An automated ImageXpressMicro imaging system from
Molecular Devices equipped with a 300W Xenon-arc lamp
from PerkinElmer, 10X Plan Fluor 0.3 numerical aperture
objective from Nikon, and a Photometrics CoolSnapHQ
camera (1,392 × 1,040 pixels) from Roper Scientific was used
to acquire images. Filipin images were acquired using
377/50 nm excitation and 447/60 nm emission filters with a
415 dichroic long-pass filter. GFP images were acquired using
472/30 nm excitation and 520/35 nm emission filters with a
669 dichroic long-pass filter. Filter sets assembled in Nikon
filter cubes were obtained from Semrock (Rochester, NY).
Images were also acquired using a Leica DMIRB micro-
scope (Leica Mikroscopie und Systeme GmbH, Germany)
equipped with a Princeton Instruments (Princeton, NJ) cooled
charge-coupled device camera driven by Image 1/MetaMorph
Imaging System software (Universal Imaging Corporation,
PA). Images were acquired using a high-magnification oil
immersion objective (63×, 1.4 numerical aperture objective).
Filipin images were acquired using an A4 filter cube obtained
from Chroma Technology Corp (Brattleboro, VT) with 360-
nm (20-nm bandpass) excitation filter and 465-nm (40-nm
bandpass) emission filter.
Imaging and analysis
A method described previously was used to quantify the
cholesterol accumulation in LSOs. NPC1 mutant cells show a
bright region of filipin labeling near the cell center,
corresponding to the sterol-loaded LSOs. The 384-well plates
containing cells were imaged for filipin using a 10× 0.3
numerical aperture objective dry objective on an Image-
XpressMicro automatic fluorescence microscope. Four images
were acquired from each well. Images were analyzed using
MetaXpress image-analysis software. First, all images were
corrected for slightly inhomogeneous illumination as
described previously (43). A background intensity value was
set as the fifth percentile intensity of each image, which
corresponds to intensity outside the cells, and this intensity
value was subtracted from each pixel in the image. At the
plating density used in this study, all fields maintain at least
5% of the imaged area cell free. We calculated the LSO ratio,
which is the ratio of filipin fluorescence intensity in the
brightly labeled centers of the cells in the field divided by the
total area of the cells. The LSO ratio is determined using two
thresholds that are applied to the filipin images. A low
threshold is set to include all areas occupied by cells. The
outlines of cells using the low threshold are similar to the cell
outlines in transmitted light images. A higher threshold is
then set to identify regions brightly stained with filipin in
cells. The thresholds were chosen for each experiment.
LSO ratio (PFI) = total intensity above high
− thresholded filipin intensity/
number of pixels above low
− thresholded filipin intensity.
Amplex Red assay for cholesterol
GM18453 cells were plated in 96-well plates and treated
with DMSO or AUY922 at different concentrations for 72 h.
For free cholesterol quantification, an Amplex Red assay kit
(Abcam; catalog no. ab65359) was used following the manu-
facturer's protocol for lipid extraction and fluorometric
measurement.
NPC1 immunolocalization in NPC1I1016T human
fibroblasts
GM18453 cells were treated with 100 nM AUY922 or DMSO
solvent control for 72 h. Cells were then incubated with 50 μg/
ml Alexa546-LDL in MEM growth medium supplemented
with 5.5% FBS and 100 nM AUY922 or DMSO solvent control
for 4 h, rinsed with growth medium, and chased in MEM
growth medium supplemented with 5.5% FBS for 30 min.
Cells were washed three times with PBS and then fixed with
1.5% PFA in PBS. For immunostaining, cells were per-
meabilized with 0.5% saponin and 10% goat serum in PBS for
30 min. Cells were incubated with 0.8 μg/ml p-Rab anti-hNPC1
primary antibody for 2 h in the presence of 0.05% saponin
and 0.5% goat serum at room temperature, followed by
Alexa488-labeled goat antirabbit secondary antibody (1:1,000;
Life Technologies, Grand Island, NY) for 45 min at room
temperature. Finally, cells were washed three times with PBS,
and images were acquired using a Zeiss LSM 880, Airyscan
confocal microscope equipped with a Plan-Apochromat 63×
oil DIC M27 objective and 488 and 561 lasers. Z-stacks were
acquired using a step size equivalent to one airy unit.
Image analysis for measuring colocalization
To measure colocalization, a previously described method
was used (44, 45). The images were first corrected for the
background intensity. Next, a threshold was applied to the
Alexa488 images representing NPC1 protein. A mask was
generated and transferred to the Alexa546 image represent-
ing LE/Ly compartments containing LDL. The intensity in
the region under the mask was recorded representing the
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colocalized region. The ratio of intensity in the Alexa546-
positive region and total threshold region (Alexa488 +
Alexa546) gives percent colocalization.
Endoglycosidase H assay
Vehicle control or HSP90 inhibitor-treated NPC1I1061T
mutant fibroblasts were lysed with RIPA lysis buffer and
endoglycosidase H (EndoH) assay was performed as described
previously (46). For EndoH analysis of NPC1 protein, 20 μg of
cell lysates were incubated in 4× SDS sample buffer in the
presence or the absence of EndoH overnight at 37◦C. The
lysates were resolved on SDS-PAGE followed by immuno-
blotting with p-Rab anti-hNPC1, p-Rab anti-HSP90, and p-Rab
anti-GAPDPH antibodies. The fraction of the intensities of
EndoH-sensitive (EndoHS) and EndoH-resistant (EndoHR)
bands for each condition were quantified and plotted.
Western blotting
Western blot analysis was performed on HSP90 inhibitor-
treated human NPC1 mutant fibroblasts to measure the
expression of NPC1, HSP40, HSP70, and HSP90 using rabbit
polyclonal antibodies to NPC1, HSP40, HSP70, and HSP90.
Anti-α tubulin was used as a loading control. Secondary an-
tibodies were from Pierce for ECL or from Molecular Devices
for Eu label.
Overexpression of HSP40 and HSP70
For HSP40, NPC1 human fibroblasts were transfected with
either eGFP-vector (pCMV6-AC-GFP tagged cloning vector;
catalog no. PS100010; Origene Technologies) or eGFP-HSP40
(DNAJB11 [NM_016306] Human Tagged ORF Clone; catalog
no. RG200216; Origene Technologies) plasmid using an
Amaxa human dermal fibroblast kit and T20 protocol. For
HSP70, NPC1 human fibroblasts were transfected with either
eGFP-vector or eGFP-HSP70 (Addgene; catalog no. 15215)
plasmid using an Amaxa human dermal fibroblast kit and
manufacturer-recommended U2OS protocol. After nucleo-
fection, cells were plated in 2-cm poly D-lysine coated cover-
slip dishes. Cells were incubated for 72 h, washed with PBS,
fixed with 1.5% PFA, and stained with 50 μg/ml filipin. Wide-
field fluorescence microscope images were acquired using
FITC and UV filters and a 10× objective. Images were
analyzed to determine LSO (PFI per cell) ratio values in GFP-
labeled cells as described previously.
RESULTS
Activity of HSP90 inhibitors in lowering lysosomal
cholesterol storage in NPC1 mutant cells
We tested the effects of six HSP90 inhibitors on
lysosomal cholesterol accumulation in NPC1I1061T
mutant human fibroblasts. Cells plated in 384-well
plates were treated with 17-AAG (47), AUY922 (47),
ganetespib (48), AT13387 (49–51), SNX2112 (52), or TAS-
116 (53) at concentrations ranging from 0.5 nM to 10 μM
depending on the reported potency of the compounds.
The fibroblasts were treated with inhibitors for 72 h
followed by fixation, staining with filipin and Draq5,
and fluorescence microscopy analysis. Free (i.e., unes-
terified) cholesterol levels in perinuclear compartments
brightly labeled by filipin in LSOs/PFIs were measured
as described previously (21, 43). All data were normal-
ized to matched DMSO controls; so a value of one in-
dicates no correction, and values below one indicate
reduction of stored free cholesterol. Figure 1A shows
the effects of six HSP90 inhibitors. All the inhibitors
tested showed dose-dependent effects after a 72-h
treatment. AUY922 was the most potent compound,
and it partially corrects the NPC1 phenotype below 0.5
nM. The dotted line on the plot indicates DMSO con-
trol, and the value of one means no correction. The
black trace in the plot shows the PFI in DMSO-treated
WT GM5659 fibroblasts. The effectiveness of some of
the HSP90 inhibitors was reduced at higher concen-
trations, and we saw a similar reversal with high con-
centrations of HDACi (21). This may be due to the
pleiotropic effects of HSP90 inhibition. The effective
concentrations of the HSP90 inhibitors in this assay
were generally comparable to values for blocking the
growth of cancer cells in culture (49, 50, 52–54),
although there was variability of the potency of the
compounds in blocking different tumor cells. Detailed
statistical analysis was performed using GraphPad
Prism software, and the P values calculated using the
ANOVA Kruskal-Wallis multiple comparison test are
shown in supplemental Fig. S1A–F. There is a large
variation in the published IC50 values for HSP90 in-
hibitors. Even with cell-free assays, the reported values
for some inhibitors vary widely (55–59). Nevertheless,
there was fair correlation between the biochemical IC50
and the midpoint of LSO/PFI curves. For instance, the
reported IC50 for ganetespib is 5 nM (59), and we see the
half maximal effect at 5 nM. For TAS-116, the reported
value is 69 nM (53), and we see the half maximal effect
near that dose.
Representative low-magnification images of
GM18453 cells treated with DMSO or optimal concen-
trations of all HSP90 inhibitors are shown in Fig. 1B.
Images shown were acquired at 10× magnification on
automated high-throughput microscope Image-
XpressMicro. Representative high-magnification images
acquired using a 63× objective are also shown in Fig. 1C.
The images in the figure are of NPC1 skin fibroblasts
GM18453 treated with DMSO and HSP90 inhibitors at
optimal concentrations labeled with filipin. All HSP90
inhibitors tested show substantial reduction in free
cholesterol in PFI compared with DMSO-treated cells.
The reduction in free cholesterol in HSP90 inhibitor-
treated cells was similar to the reduction we reported
previously for cells treated with 10 μM vorinostat (21).
We compared changes in free cholesterol in
GM18453 cells using filipin and an Amplex Red assay
of cholesterol. Since the Amplex Red assay measures
total free cholesterol, we compared this with the total
filipin fluorescence per cell. As shown in Fig. 2A, there
is only a slight drop in total cholesterol as the LSOs are
cleared off cholesterol, and the filipin and Amplex Red
values show very similar effects. The small effect on
total cholesterol is in agreement with earlier studies
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Fig. 1. Effect of HSP90 inhibitors on GM18453 NPC1 human fibroblasts: A: GM18453 fibroblast (homozygous I1061T) cells were
treated with HSP90 inhibitors 17-AAG, AUY922, ganetespib, AT13387, SNX2112, TAS-116, and DMSO-treated WT-GM5659 at various
doses for 72 h, fixed, and stained with filipin and Draq5. Images were acquired on an ImageXpressMicro using 10× magnification.
Each data point is an average of the PFI per cell values from 48 images. Each image contains about 500–700 cells. Each data point in
the plot is from three independent experiments ±SE. LSO values in DMSO-treated cells were measured in each experiment for
normalization and shown as a dotted line. The value of one indicates no correction. B: Representative low-magnification high-
throughput filipin images of GM18453 cells treated with DMSO or optimal concentrations of HSP90 inhibitors acquired using 10×
objective are shown. Vorinostat treatment was used as a positive control. The filipin intensity in perinuclear organelles of cells
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that showed that NPC mutant cells have elevated
cholesterol in the LSOs, but elsewhere, the cholesterol
content is reduced (60). To test whether the observed
effect depended on the expression of the mutant NPC1
protein, we treated U2OS-SRAshNPC1 (NPC1−/−) cells
with three HSP90 inhibitors at varying concentrations
for 72 h. The PFIs per cell were measured by filipin
labeling as described previously. Figure 2B shows that
there was no correction of the NPC1 phenotype in
these cells, demonstrating that the effect observed is
specific for cells carrying a mutant NPC1 protein and
not an NPC1-independent effect similar to HPCD
treatment (61).
Time course of HSP90 inhibitors on NPC1I1061T
fibroblasts
We measured the time course for effects of HSP90
inhibitors on NPC1I1061T mutant human fibroblasts.
Figure 3 shows the effect of 17-AAG and AUY922 at
various doses after 1, 2, or 3 days. Neither of the in-
hibitors tested had a large effect at 24 h, but both
showed dose-dependent effects at 48 h and similar or
somewhat greater effects after 72-h treatment. This
time course is consistent with the need to synthesize and
transport new NPC1 proteins to LE/Ly in response to
the drug treatment as has been proposed for HDACi
treatment (11, 18, 21). The t1/2 of WT NPC1 protein that
has passed beyond the ER is 1–2 days (11), and a similar
lifetime was observed for NPC1I1061T in human fibro-
blasts treated with vorinostat (18).
AUY922 treatment rescues the trafficking of mutant
NPC1 protein in NPC1I1061T fibroblasts
In cultured fibroblasts, approximately half of the
WT NPC1 protein is degraded rapidly, and for many
mutants, most of the synthesized protein is degraded
with very little reaching the LE/Ly (11, 18). To measure
export of NPC1I1061T out of the ER, we measured
acquisition of resistance to EndoH, which occurs after
proteins are exported from the ER. We measured the
effect of AUY922 on acquisition of EndoHR using a
method described by Balch et al. (29, 62–64). The cell
lysates from DMSO and AUY922-treated NPC1I1061T
fibroblasts were incubated with EndoH to cleave
immature high-mannose N-linked glycans found in the
ER, resulting in an increase in migration using SDS-
PAGE (EndoHS). In immunoblots, the band intensities
for EndoHR and EndoHS bands were measured (Fig.
4A, B). Treatment of NPC1I1061T fibroblasts with
AUY922 substantially increases exit from the ER as
shown by the decrease in EndoHS fraction (clear bars)
after AUY922 treatment in a dose-dependent manner.
The data from two separate experiments are shown in
Fig. S2.
treated with HSP90 inhibitors is reduced, demonstrating the clearance of cholesterol. DMSO, AUY922 (40 nM), ganetespib (40 nM),
17-AAG (370 nM), AT13387 (120 nM), SNX2112 (370 nM), TAS-116 (3.33 μM), 17-AAG (370 nM), and vorinostat (10 μM), Size bar
represents 100 μm. C: Representative high-magnification filipin images of NPC1 GM18453 fibroblast treated with HSP90 inhibitors at
optimal concentrations acquired using 63× objective are shown. DMSO, AUY922 (40 nM), ganetespib (370 nM), 17-AAG (0.37 μM),
AT13387 (120 nM), SNX2112 (120 nM), and TAS-116 (1.11 μM). Size bar represents 50 μM.
Fig. 2. A: Total cholesterol estimation. A plot showing total
cholesterol concentration in AUY922-treated GM18453 cells as
measured by Amplex Red biochemical method (black) and
average filipin per cell (red). Error bar represents SE. B:
Treatment of HSP90 inhibitors on U2OSshNPC1 cells. U2OS-SRA-
shNPC1 cells were treated with HSP90 inhibitors at varying
doses ranging from 5 nM to 10 mM for 72 h, fixed, and stained
with filipin and Draq5. Images were acquired on an Image-
XpressMicro using a 10× objective. Each data point is an average
of 48 images. Each image contain ∼500–700 cells. Each data
point in the plot is from three independent experiments. Error
bar represents ±SE.
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Colocalization of NPC1 and LDL
To determine whether treatment with an HSP90 in-
hibitor improved trafficking of NPC1I1061T protein to
LE/Ly, we treated GM18453 NPC1I1061T cells with 100
nM AUY922 or solvent control DMSO for 72 h. The
cells were then incubated with Alexa546 LDL for 3.5 h
followed by a 0.5 h chase to deliver labeled LDL to LE/
Ly (45, 65, 66). The fibroblasts were fixed, and NPC1
protein was detected by immunofluorescence (Fig. 4C).
Representative sum projected images are shown.
Additional representative images are also shown in Fig.
S3. The mutant NPC1 protein does not colocalize with
Alexa546 LDL in LE/Ly in the DMSO-treated cells (i.e.,
red and green puncta are not colocalized). After 72 h of
treatment with 100 nM AUY922, a large fraction of the
mutant NPC1 protein localizes in yellow puncta in the
overlay, showing that NPC1 and LDL are in the same
organelles. The quantification of the Alexa488 (NPC1)
signal colocalizing with Alexa546 LDL after either
DMSO or AUY922 (100 nM) treatment was carried out
as described in the Materials and methods section (44,
45). Shown in Fig. 4D are the data from two indepen-
dent experiments, and each dot represents a single
image. The data show that AUY922 treatment results in
a significant increase in colocalization of NPC1 with
endocytosed LDL. This indicates that treatment with
AUY922 leads to delivery of the mutant NPC1 to the
organelles in which LDL is releasing cholesterol, and
this NPC1I1061T effectively aids in transporting choles-
terol out of these organelles.
Effect of HSP90 inhibitor treatment on expression
of other proteins
Chaperone-mediated protein folding involves syn-
chronized interplay of multiple chaperones and
cochaperones, so inhibiting one protein results in
perturbation/modulation of other chaperones and
cochaperones in the pathway. It has been reported that
inhibiting HSP90 results in upregulation of HSP70 in
cells (67, 68). HSP90 inhibitors do not generally change
the expression of the HSP90 protein, but they inhibit its
activity by binding at the N-terminal catalytic ATP-
binding site (36, 37, 54, 69). To further understand the
mechanism by which HSP90 inhibitors reverse the
NPC1 mutant phenotype, we measured the expression
of HSP90, HSP70, and HSP40 as well as the NPC1
protein.
NPC1I1061T human fibroblasts were treated with
either 17-AAG (1 μM), AUY922 (40 nM), ganetespib (100
nM), or DMSO (vehicle control). After 72 h of treatment
with compounds or solvent control, cells were lysed,
followed by immunoblot analysis. Figure 5A shows
representative bands from one experiment. Average
band intensities for three independent experiments
were quantified and normalized to loading control
(tubulin) and compared with the parallel DMSO-treated
band (Fig. 5B). The dots shown on each bar represents
values from independent experiments, and the data
plotted are ±SE. The results indicate that HSP90 in-
hibitor treatment results in significant increases in
expression of NPC1, HSP70, and HSP40, but there is no
significant change in HSP90 expression. The increase
in HSP70 and HSP40 expression after HSP90 inhibitor
treatment is in agreement with previously published
reports (12, 38, 39, 67, 68).
HSP70 (HSPA1A) overexpression
In order, to determine whether increased HSP70
expression plays a role in correction of the NPC1I1061T
mutant phenotype, we overexpressed HSP70 in
NPC1I1061T human fibroblasts. We transiently trans-
fected eGFP-HSP70 in GM18453 cells. Representative
images for eGFP-Vector transfected and eGFP-HSP70
transfected cell are shown in Fig. 5C. Figure 5D shows
the plot of PFI in GFP-positive cells that overexpressed
either Vector (control) or HSP70. The data plotted are
from three independent experiments (35, 40–44) im-
ages, and each dot represents a single cell. We tried to
determine if the level of HSP70 expression is correlated
with the decrease in cholesterol accumulation (Fig. S4A,
B). Even a small amount of HSP70 overexpression
Fig. 3. Time course of treatment with HSP90 inhibitors:
GM18453 fibroblasts were treated with A. 17-AAG or B.
AUY922 at varying doses for 24, 48, and 72 h, fixed, and stained
with filipin and Draq5. Images were acquired on an Image-
XpressMicro using a 10× objective. Each data point is an average
of 500–700 cells per image and 48 images. Each data point in the
plot is from three independent experiments. Error bar repre-
sents ±SE.
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Fig. 4. Localization and stability of NPC1 protein after HSP90 inhibitor treatment. A: GM18453 cells were treated with AUY922 at
varying doses for 72 h, after which cells were lysed with RIPA lysis buffer. For EndoH analysis of NPC1 protein, 20 μg of cell lysates
were treated in the presence or the absence of EndoH overnight at 37◦C. The lysates were resolved on SDS-PAGE followed by
immunoblotting with p-Rab anti-hNPC1, p-Rab anti-HSP90, and p-Rab anti-GAPDH antibodies. B: The fraction of the intensities of
EndoHS and EndoHR bands for each condition. C: GM18453 fibroblasts were treated with 100 nM AUY922 or solvent control DMSO
for 72 h. The cells were incubated with Alexa-546 LDL for 3.5 h followed by a 0.5 h chase to deliver labeled LDL to LE/Ly. The
fibroblasts were fixed and immunostained with primary p-Rab-anti hNPC1 antibody followed by goat-anti-Rab-A488 labeled sec-
ondary antibody and detected by immunofluorescence. Images were acquired by confocal microscopy. Representative transmitted
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resulted in a reduction in PFI when compared with
control Vector. These results indicate that the increased
expression of HSP70 aids in rescuing the NPC1I1061T
mutant phenotype.
HSP40 (DNAJB11) Overexpression
HSP40 is a co-chaperone of HSP70, so we tested the
role of HSP40 expression in the correction of
NPC1I1061T mutant phenotype. We overexpressed
HSP40 in NPC1I1061T human fibroblasts by transiently
transfecting eGFP-HSP40 in GM18453 cells. Represen-
tative images for eGFP-vector transfected and eGFP-
HSP40 transfected cells are shown in Fig. 5E. Figure
5F shows a plot of the LSO ratio in GFP-positive cells
that did or did not overexpress HSP40. The data are
from three independent experiment (24–30) images,
and each dot represents a single cell. As with HSP70
overexpression, even a small level of HSP40 expression
reduced the PFI (Fig. S4C, D), and there was only a small
benefit at most from higher levels of HSP40. These
results indicate that the increased expression of HSP40
also results in rescuing the NPC1I1061T mutant
phenotype.
GRP94 inhibitors
The HSP90 family of genes includes HSP90A (cyto-
solic), HSP90B (ER), and tumor necrosis factor receptor-
associated protein (mitochondrial) proteins. The in-
hibitors that we described so far are pan inhibitors or
just inhibit HSP90A (TAS-116) (70). The TAS-116 results
indicated that inhibition of the cytosolic form of HSP90
alone was effective. In order to examine another
HSP90 isoform, we tested inhibitors selective for the
ER-resident HSP90B1 class of chaperones, GRP94
(71–76). GM18453 fibroblasts were treated with five
different GRP94 inhibitors (Table 1) for 72 h, and the
PFI per cell was measured (Fig. 6). The GRP94-selective
compounds did not rescue the NPC1I1061T phenotype.
These data indicate specificity for cytosolic HSP90A
inhibition in rescuing NPC1 phenotype.
HSP70 activators
It has been reported that arimoclomol reduces the
size of lysosomes in NPC1−/− fibroblasts, and it reduced
the ataxia and improved behavioral symptoms in an
Npc1−/− mouse model (34). The compound arimoclomol
has been described as an HSP70 coinducer, but we
could find no peer-reviewed publications supporting
this. The efficacy and safety of arimoclomol is being
tested on NPC1 patients in a clinical trial (77). We tested
arimoclomol on GM18453 human NPC1 fibroblasts at
concentrations ranging from 1.6 to 500 μM for 3 or 5
days (Fig. 7A). We did not observe correction of the
cholesterol storage in NPC1I1061T human fibroblasts. At
higher concentrations and longer exposure, the
phenotype worsened as shown by increases in the PFI
per cell. In order to determine whether arimoclomol
upregulates HSP70 protein expression in our cell cul-
ture model, we performed Western blot analysis on
GM18453 cells treated with arimoclomol (50 and 400
μM) for 3 and 5 days (Fig. 7B) and plotted the results
from three independent experiments (Fig. 7C). The
results indicate that arimoclomol treatment by itself
does not upregulate HSP70 expression in GM18453
fibroblasts.
Cotreatment of arimoclomol with AT13387 and heat
shock transcription factor 1a
Since treatment with HSP90 inhibitors increased
HSP70 expression, we tested whether arimoclomol in
combination with one of the HSP90 inhibitors would
show synergistic effects. NPC1 human fibroblasts
GM18453 were treated with compounds one day after
plating. Cells were treated with arimoclomol at 0, 0.5, 1,
2, 10, 40, and 100 μM in combination with AT13387
(onalespib) at 0, 0.04, 0.12, 0.37, 1.11, 3.33, and 10 μM and
compared against DMSO-treated controls. The range of
drug dosages was made to contain a large gradient of
concentrations in screening media as described previ-
ously (43). Figure 7D shows the heat map of the com-
bination treatments. The treatment with AT13387 did
show correction of NPC1 phenotype as expected, but
there was no statistically significant synergistic effect
from including arimoclomol.
Heat shock transcription factor 1 (HSF1) is the master
regulator of HSP gene transcription (78). Arimoclomol
is described as a coactivator that prolongs the binding
of activated HSF1 to heat shock elements in the pro-
moter regions of inducible HSP genes (79). A study of
beneficiary effects of arimoclomol in NPC1 disease
reported that NPC1 fibroblasts subjected to heat shock
exhibited activation of HSF1 (34). Hence, we tested the
effect of arimoclomol in combination with HSF1-
activating compound HSF1a (80, 81) and measured the
cholesterol level using the LSO filipin assay. As shown
in Fig. S5, we did not see a beneficial effect of HSF1a
with or without arimoclomol.
DISCUSSION
Wereport here that treatmentofNPC1mutanthuman
fibroblasts with several HSP90 inhibitors at nanomolar
concentrations leads to clearance of the accumulated
cholesterol in the LE/Ly of human homozygous
NPC1I1061T fibroblasts in a dose-dependent manner.
Based on the ineffectiveness of these inhibitors on
light and sum projected images of fluorescently labeled NPC1 and LDL are shown. Size bar represents 25 μm. D: Quantification of
the colocalization of Alexa488 (NPC1) and Alexa546 (LDL) signals after either DMSO or AUY922 (100 nM) treatment. The data are
from two independent experiments, and each dot represents single image. Mann-Whitney statistical analysis (GraphPad Prism) was
used. P < 0.0001.
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Fig. 5. Effect of HSP90 inhibitors on expression of other chaperones: GM18453 fibroblasts were treated with 17-AAG (1 μM),
AUY922 (40 nM), or ganetespib (100 nM). As a control, cells were treated with DMSO. After 72 h of treatment with compounds or
solvent control, cells were lysed and immunoblotted for various proteins. After resolving bands on 4–12% Bis-Tris gel, proteins were
transferred to a PVDF membrane and probed with p-Rab anti-hNPC1 antibody, p-Rab anti HSP70, p-Rab anti HSP40, and p-Rab anti
HSP90. Tubulin (mouse monoclonal) was used as a loading control. A: Lane 1: DMSO; lane 2: 1 μM 17-AAG; lane 3: 40 nM AUY922;
and lane 4: 100 nM ganetespib. B: Plot showing quantification of immunoblot bands normalized to tubulin and DMSO-treated fi-
broblasts. Dotted indicates DMSO control. P values for NPC1, HSP90, HSP70, and HSP40 were 17-AAG (green): 0.001, not significant
(ns), 0.008, 0.05; AUY922 (red): 0.03, ns, 0.0002, 0.03 and ganetespib (blue): 0.0001, ns, 0.0009, 0.05, respectively. C: GM18453 cells were
transiently transfected with eGFP-vector or eGFP-HSP70 and incubated for 72 h. Cells were washed with PBS, fixed with 1.5% PFA,
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NPC1−/− cells, we infer that the clearance is due to a
direct impact on the NPC1 protein and not a general
bypass of theNPC1-dependent pathways as is seen in cells
treated with cholesterol-chelating cyclodextrins (61).
The beneficial effect of HSP90 inhibitors is associ-
ated with improved trafficking of the NPC1 protein out
of the ER and delivery to LE/Ly. In untreated cells, the
majority of NPC1I1061T protein is EndoH sensitive,
indicating failure to exit the ER (29). After the treat-
ment with AUY922 for 3 days, the majority of the
NPC1I1061T has exited the ER and shows good colocali-
zation with internalized LDL in LE/Ly. In order to start
understanding how inhibition of HSP90 might improve
folding of NPC1I1061T and its exit from the ER, we
examined he effects of HSP90 inhibitors on expression
of other chaperone proteins. As reported previously,
HSP70 and HSP40 levels were increased when HSP90
was inhibited (32, 33), and this was accompanied by an
increase in NPC1 protein in the cells. Transient over-
expression of HSP70 or HSP40 also reduced the
cholesterol storage significantly. Although proper
folding of proteins is facilitated in the ER by various
molecular chaperones, RNA-Seq data in cells treated
with AUY922 or onalespib did not show an increase in
binding protein, calnexin, or calreticulin (data not
shown). It is unclear how even slightest increase of
cytosolic chaperones such as HSP40 and HSP70 (Figs.
5C–F and S4A–D) affect the folding of NPC1, which
has relatively small cytoplasmic sequences. Various
mechanisms have been proposed for the rescue of
NPC1 mutant cells by increasing HSP70. One study
claims that increasing HSP70 can rescue NPC1−/− cells,
which suggests that there are other unknown mecha-
nisms for rescue of cholesterol storage (82). Another
article suggests that HSP70 can affect the proteostasis
of mutant NPC1—allowing more of the mutant NPC1 to
exit the ER as a properly folded protein (14). A third
article proposes that HSP70 can extend the lifetime of
NPC1 by blocking ubiquitination and proteasome-
mediated degradation (12). Thus, further in-depth
studies will be required to understand the detailed
mechanism by which cytosolic HSP90/HSP70/HSP40
chaperone machinery is involved in folding of large
transmembrane-spanning protein like NPC1.
A recent study examined the effects of modulating
the HSP70 chaperone/cochaperone complex on a large
number of NPC1 variants (14). That study focused on
the effects of an allosteric inhibitor, JG98, which alters
the interactions of HSP70 with cochaperones, especially
the Bcl-2-associated athanogene family of cochaper-
ones (83, 84). As with the study of HDACis (18), it was
found that JG98 corrected the ER retention and
degradation of many NPC1 variants (14). This study
examined SREBP2 activity, which is affected by the
release of cholesterol from LSOs, and the results indi-
cate that JG98 was facilitating release of cholesterol
from LSOs in NPC1I1061T cells. Overall, our results
corroborate these findings on the importance of HSP70
and other chaperones and extend them by directly
demonstrating trafficking of NPC1I1061T to late endo-
somes and lysosomes containing LDL and showing
reduction of filipin-labeled cholesterol in these organ-
elles. Much additional work will be required to develop
optimal strategies to target these chaperone networks to
treat NPC1 patients.
Since NPC1 protein is folded initially in the ER, we
tested inhibitors of the ER-specific member of the
HSP90 family, GRP94 (72–74, 76). The GRP94-selective
inhibitors were not effective in rescuing the cholesterol
storage defect in NPC1I1061T cells. This is consistent with
a downstream effect of HSP90 inhibitors, such as
increasing cytosolic HSP70 expression, rather than a
direct effect of an HSP90 protein on the NPC1 protein
in the ER. Our data showing rescue of NPC1 phenotype
with HSP40 overexpression are in agreement with
published reports. It has been shown that treatment of
HEK293 cells with 17-AAG increases the expression of
HSP70 mRNA, and the effect is enhanced by a mild
and stained with 50 μg/ml filipin. Images were acquired using GFP and A4 filters using a 20× dry objective. Size bar represents
25 μm. D: PFI was measured in GFP-positive cells and plotted. Dot plots showing data from three independent experiments ±SE. Each
dot represents an individual cell. Mann-Whitney statistical test was performed, P < 0.0001. E: GM18453 cells were transiently
transfected with eGFP-vector or eGFP-HSP40 and incubated for 72 h. Cells were washed with PBS, fixed with 1.5% PFA, and stained
with 50 μg/ml filipin. Images were acquired using GFP and A4 filters using a 20× dry objective. Size bar represent 10 μm. F: PFI was
measured in GFP-positive cells and plotted. Dot plots showing data from three independent experiments ±SE. Each dot represents an
individual cell. Mann-Whitney statistical test was performed, P < 0.0001.
Fig. 6. Effect of GRP94 Inhibitors on NPC1 cells: GM18453
fibroblasts were treated with GRP94 inhibitors BB1, BB2, BB3,
BB4, and BB5 at varying doses for 72 h, fixed, and stained with
filipin and Draq5. Images were acquired on ImageXpressMicro
using a 10× objective. Each data point is an average from three
experiments and 72 images total, each image contained
∼300–500 cells. Error bar represent ±SE.
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Fig. 7. A: Effect of HSP70 coinducer arimoclomol on NPC1 human fibroblasts: GM18453 fibroblasts were treated with HSP70
activator arimoclomol for 72 h or 120 h at doses ranging from 50 to 500 μM, fixed, and stained with filipin and Draq5. Images were
acquired on ImageXpressMicro using a 10× objective. Each data point is an average of 48 images. Each image contain ∼500–700 cells.
Each data point in the plot is from three independent experiments ±SE. B: Western blot of arimoclomol-treated NPC1 human
fibroblast: GM18453 fibroblasts were treated with HSP70 activator arimoclomol for 72 h or 120 h at 50–400 μM. Cells were lysed, and
Western blot was run using protocol described in the Materials and methods section. Membrane was probed with p-Rab-anti-HSP70
and p-Rab-anti-GAPDH antibodies. Bands were visualized using ECL on a Licor Fc system and quantified. C: Data in plot are from
three independent experiments. There was no significant difference in HSP70 expression compared with DMSO-treated cells. Error
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heat stress (85). It will be valuable in the future to
explore treatments that enhance HSP70 activity (and
other chaperones) for the treatment of NPC1 disease.
We tested arimoclomol treatment on disease-relevant
NPC1I1061T cells, which was previously reported to
enhance HSP70 as well as HSF1 activation in NPC−/−
cells (34). However, we did not observe any reduction in
cholesterol storage in NPC1I1061T cells at concentrations
up to 0.5 mM for 3 or 5 days. Nor did we see any in-
crease in HSP70 expression in NPC1I1061T cells after
arimoclomol treatment (Fig. 5B, C). A related com-
pound, bimoclomol, has been reported to enhance
stress responses but it requires a mild independent
activation of stress for this effect (86). It is possible that
this type of stress was not present in our cells. Based on
the reports of increased HSF1 activation upon arimo-
clomol treatment and a study reporting combination
treatment of arimoclomol with celastrol—an HSF1-
activating compound (34, 79), we treated NPC1I1061T
cells with a combination of arimoclomol and an HSF1-
activating compound (HSF1a) (80, 81). This did not yield
any additional correction of the NPC1 phenotype. In
contrast when we combined arimoclomol with AT13387
compound, which has shown to correct the NPC1
phenotype (Fig. 1), we did observe the expected
correction from AT13387, but there was no synergistic
enhancement by arimoclomol combination treatment
(Fig. 7D). Taken together, our data suggest that the
therapeutic effect of arimoclomol treatment on
NPC1−/− cells might be due to off-target effects since
arimoclomol has been reported to inhibit several key
regulatory enzymes at micromolar concentrations (87).
This result suggests that further exploration of the
mechanism of action of arimoclomol is warranted
especially since the pharmaceutical form of arimoclo-
mol is currently undergoing clinical trials (https://
ClinicalTrials.gov/show/NCT02612129) (77). There are
numerous mutations reported in the human NPC1 gene
that are associated with NPC1 disease (2, 3, 5, 7). The
most common mutant protein, NPC1I1061T, exits the ER
inefficiently and is mostly degraded (18). We have
previously shown that several other NPC1 missense
mutations could function if they could pass through
the ER quality control processing. In this study, we only
tested NPC1I1061T, but we found that the results were
very similar to HDACi treatment in that we observed
increased protein stability and proper localization of
the mutant protein. In conclusion, we report here the
therapeutic potential of pan HSP90 inhibitors or
HSP90A-selective inhibitors for the treatment of NPC1
disease. Efforts are under way to test these compounds
in a mouse model. We note that although TAS-116 is not
as potent as other HSP90 inhibitors tested, it is selective
for HSP90α and HSP90β (70) in the cytosol/nucleus and
does not target GRP94 in ER and tumor necrosis factor
receptor-associated protein 1 in mitochondria. In addi-
tion, unlike the other HSP90 inhibitors, TAS-116 is an
oral drug that is currently in phase 3 clinical trial of
gastrointestinal stromal tumors (88, 89). The promising
effect of HSP90 inhibition and HSP70 overexpression
provides a basis for further investigations of protein
chaperones in the treatment of NPC1 disease.
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bars represent SE. C: Plot showing quantification of immunoblot bands from DMSO or 50 and 400 μM arimoclomol treated NPC1
fibroblasts for 72 and 120 h. Data were normalized to tubulin and DMSO-treated fibroblasts. Dotted indicates DMSO control. No
statistically significant difference was observed. D: Cotreatment of AT13387 and arimoclomol on GM18453 NPC1 fibroblasts.
GM18453 fibroblasts were plated in 384-well plates and coincubated with arimoclomol and HSP90 inhibitor AT13387 in a dose-
dependent manner for 72 h. Heat map value represents the average PFI of three independent experiments with four replicate
per wells per plate, each image had 100–300 cells, normalized to DMSO-treated cells. LSO values less than one represent a decrease in
cholesterol storage, and values greater than one identify an increase in cholesterol storage.
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